

# Gastrointestinal (GI) Disease-Oriented Team

---

Clinical Research Treatment Trial Flowchart



■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

**NEOADJUVANT**

GI

**UCI 20-09/SHORT**  
(Radiation + TASOX)

Coord: A. Luna  
Accrual: 1/9

**ADJUVANT**

**NRG-GI008/CIRCULATE**  
(ctDNA guided tx)

Coord: A. Luna  
Accrual: 1/5

**INTRA-OPERATIVE**

**UCI 20-163**  
(SOC vs CG-100 Intraluminal)

Coord: M. Nguyen  
Bypass Device

Tumor Location

**A022104/Janus Trial**  
(Triplet vs. double chemo)

Coord: A. Luna  
Accrual: 1/5

**NRG-GI005/COBRA**  
(SOC vs mFOLFOX6 or CAPOX or surveillance)

Coord: LM Aguilar  
Accrual: 2/5

Mutations

**EA2201**  
(Nivo + Ipi + radiation)

Coord: K. Ghio  
Accrual: 0/3

**UCI 20-43**  
(TAS102 + irinotecan)

Coord: Krissy Ghio  
Accrual: 2/11

**UCI 21-67**  
(Epacadostat + short course radiation + chemo)

Pending IRB, budget, contract



**1L METASTATIC**

**UCI 22-07**  
(BXQ-350 + mFOLFOX7 and bevacizumab)  
Coord: A. Luna  
Accrual: 2/5

**UCI 21-110**  
(only EC naïve patients with BRAFV600E CRC)  
Encorafenib + cetuximab + ERAS-007  
Coord: P. Yang  
Accrual: 6/15

**A022101**  
(at least 4 months of chemo once metastatic disease is confirmed)  
Coord: A. Luna  
Accrual: 0/2

**2L METASTATIC**

**S2107**  
(Encorafenib + cetuximab +/- nivo)  
Coord: LM Aguilar  
Accrual: 0/3

**UCI 21-208**  
(nti-DR5 targeting pentameric Igm antibody IGM-8444)  
Coord: B. Huynh  
Accrual: 4/8

**3L METASTATIC**

**UCI 22-87**  
(KRAS inhibitor)  
Coord: C. Gonzalez  
Accrual: 0/20

**UCI 21-39**  
(Pembro + TATE)  
Coord: M. Duron  
Accrual: 17/20

**UCI 22-131**  
(XL092 + atezolizumab vs. regorafenib)  
Coord: P. Yang  
Accrual: 3/7

**UCI 20-84**  
(HES vs. SOC TACE)  
Coord: M. Duron  
Accrual: 8/13

**UCI 23-101**  
(Nivo + BMS-986288 vs regorafenib)  
Pending activation



■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Newly Diagnosed

ECOG-EA2182  
(Mitomycin-C + 5-Fluorouracil +  
Capecitabine)  
  
Coord: K. Ghio  
Accrual: 1/3

Advanced/Metastatic

ECOG-EA2176  
(Nivolumab + Carboplatin +  
Paclitaxel)  
  
Coord: J. Koff  
Accrual: 3/5

## Neoadjuvant

**UCI 21-191**  
(SOC therapy with ctDNA testing)

Coord: A. Luna  
Pending activation

## Newly Diagnosed Metastatic

**UCI 20-87**  
(V Paclitaxel + IV 5-FU + IV leucovorin + IP paclitaxel)

Coord: L. Mejia  
Accrual: 17/20

**UCI 22-76**  
(Anti-PD-1 + chemo +/- anti-TIGIT)

Coord: L. Mejia  
Accrual: 0/10

## Recurrent

**UCI 23-78**  
(EGFR and MET-directed antibody)

Coord: TBD  
Pending activation

**UCI 22-51**  
(ASP2138)

Coord: TBD  
Pending Activation

**UCI 20-63**  
(mAbs +/- chemotherapy)

Coord: J. Koff  
Accrual: 3/10

**UCI 21-193**  
(EGFR inhibitor + mFOLFOX6 + antiPD-L1 (nivolumab))

Coord: M. Nguyen  
Accrual: 1/12

**UCI 16-94**  
(Tirapazamine, Nivolumab)

Coord: M. Duron  
Accrual: 20/40

**A022102**  
(mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab)  
Coord: J. Koff  
Pending activation

**UCI 23-109**  
(Disitamab Vedotin + Tucatinib)

Coord: TBD  
Pending activation

# Advanced Solid Tumors By Biomarker

## HER-2

**UCI 20-67**  
nti-PD-1 DF1001  
(monotherapy or combination therapy)

Coord: M. Nguyen  
Accrual: 18/20

**ETCTN-10358/DASH**  
(DS8201a + AZD6738)

Coord: M. Nguyen  
Accrual: 0/3

**UCI 21-57**  
(Bispecific antibody (anti-HER2) + CD47-blocking infusion protein)

Coord: A. Chavez  
Accrual: 4/5

**ETCTN-10495**  
(DS-8201a + Neratinib)

Coord: K. Ghio  
Accrual: 0/7

**UCI 23-66**  
(HER-2 aberrations)

Coord: TBD  
Pending Activation

## BRAF

**UCI 21-110**  
(only EC naïve patients with BRAFV600E CRC)  
Encorafenib + cetuximab + ERAS-007

Coord: P. Yang  
Accrual: 6/15

**S2107**  
(Encorafenib + cetuximab +/- nivo)

Coord: LM Aguilar  
Accrual: 0/3

**UCI 20-179**  
SHP2 Inhibitor BBP-398

Coord: A. Macaraeg  
Accrual: 1/10

Open to Accrual

## KRAS

**UCI 22-88**  
(Tri-complex inhibitor KRAS<sup>G12C</sup> (ON) and NRAS<sup>G121C</sup>(ON))

Coord: R. Chang  
Accrual: 2/25

**UCI 21-53**  
RAS-G12C inhibitor

Coord: J. Choe  
Accrual: 6/8

**UCI 22-75**  
(KRAS targeted Vaccine)

Coord: M. Duron  
Accrual: 0/7

**UCI 22-87**  
(KRAS inhibitor)

Coord: C. Gonzalez  
Accrual: 0/20

Low Accruing

## EGFR

**UCI 22-171**  
(Anti-PD-1 +/- DF9001)

Coord: M. Nguyen  
Accrual: 2/5

Pending Activation/Suspended

## CLDN18.2

**UCI 21-10**  
(Bispecific antibody (anti-CLDN18.2 + anti-4-1BB))

Coord: K. Ghio  
Accrual: 7/10

**UCI 23-108**  
(TST001 as Monotherapy or in Combo w/ Nivo or SOC)

Coord: TBD  
Pending Activation



**UCI 23-85**  
 (BA3182 + (EPCAM)/CD3 Antibody)  
  
 Coord: TBD  
 Accrual: 0/5

**UCI 21-146**  
 (Anti-Tissue Factor monoclonal antibody-BCNvcMMAE conjugate)  
  
 Coord: C. Kang  
 Accrual: 4/11

**UCI 21-12**  
 (BA3182 + RMC-5552 (mTORC1 inhibitor))  
  
 Coord: R. Chang  
 Accrual: 1/10

**ETCTN-10579**  
 (ZEN003694 (ZEN-3694) + capecitabine)  
  
 Coord: P. Yang  
 Accrual: 0/4

**UCI 23-35**  
 (BMS-986442 in Combination with Nivolumab or Chemotherapies)  
  
 Coord: LM Aguilar  
 Accrual: 0/10

**UCI 22-37**  
 (Inhibitor of KDM4 histone demethylase)  
  
 Coord: A. Luna  
 Accrual: 2/10

**UCI 21-247**  
 (TAB004-recombinant monoclonal antiBTLA antibody monotherapy)  
  
 Coord: B. Huynh  
 Accrual: 1/3

**UCI 22-26**  
 (Androgen and glucocorticoid receptor antagonist)  
  
 Coord: N. Ferrand  
 Accrual: 6/12

**UCI 22-221**  
 BiTe of B7-H6  
  
 (Central B7-H6 testing) HCC and Pancreatic (also NSCLC, HNSCC, CRC, and gastric))  
  
 Coord: P. Yang  
 Accrual: 1/12

# Advanced Solid Tumor



**UCI 03-03**  
(Immunologic response analysis)  
Coord: S. Ninofranco  
Accrual: 262/400

**UCI 20-101**  
(Biospecimen Collection for patients planned to start treatment)  
Coord: N. Arechiga  
Accrual: 53/80

**UCI 23-127**  
(Stress & Coping in Asian Americans with Advanced Metastatic Cancer)  
Coord: TBD  
Pending Activation

**UCI 20-04**  
(Tissue Collection)  
Coord: S. Ninofranco  
Accrual: 98/130

**UCI 22-109**  
(alonosteron buccal film vs. IV Palonosetron)  
Coord: P. Yang  
Accrual: 1/30

**UCI 23-21**  
(Exosome Gene Expression Peritoneal Fluid&Plasma in Gastrointestinal Malignancies)  
Coord: LM Aguilar  
Accrual: 0/70